Please login to the form below
somavaratan
This page shows the latest somavaratan news and features for those working in and with pharma, biotech and healthcare.
Versartis crashes as VELOCITY trial veers off track
The US biotech's somavaratan proved inferior to Pfzier’s Genotropin. US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone ... Somavaratan requires dosing only every two weeks and offers other
Latest news
-
Pfizer/Opko's long-acting growth hormone misses mark in trial
Also in the running is Versartis, whose somavaratan (VRS-317) is in late-stage trials and was recently licensed to Teijin in Japan.
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
252. Versartis. Teijin (JP). Licence Japan. Somavaratan, long-acting form of rhGH, for paediatric and adult growth hormone deficiency in phase II/III in Japan.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn
- Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn
- Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
- Novavax’s updated COVID-19 vaccine approved by FDA for emergency use
- Alzheimer’s Research UK awards Cardiff University researchers £387,000
- Actinic keratosis – a common skin condition that can lead to skin cancer
No results were found
PMHub
Red Thread
Blending brilliant writing with in-depth market access and reimbursement expertise...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
